BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/17/2020 4:08:25 AM | Browse: 865 | Download: 2632
 |
Received |
|
2019-10-16 13:10 |
|
Peer-Review Started |
|
2019-10-11 07:45 |
|
First Decision by Editorial Office Director |
|
2019-12-04 14:27 |
|
Return for Revision |
|
2019-12-04 14:27 |
|
Revised |
|
2019-12-13 13:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-12-19 07:50 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-12-22 13:31 |
|
Articles in Press |
|
2019-12-22 13:31 |
|
Edit the Manuscript by Language Editor |
|
2019-12-26 02:14 |
|
Typeset the Manuscript |
|
2020-01-09 01:10 |
|
Publish the Manuscript Online |
|
2020-01-17 04:08 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020 Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Durable response to pulsatile icotinib for central nervous system metastases from EGFR-mutated non-small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hui-Ying Li, Yu Xie, Ting-Ting Yu, Yong-Juan Lin and Zhen-Yu Yin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Key Project of Nanjing Health Bureau |
ZKX16031 |
| the Healthcare Project of Nanjing Science and Technology Committee |
201715020 |
| the Medical Key Science and Technology Development Project of Nanjing |
ZKX18014 |
| the Cadre Health Care Project of Jiangsu Province |
BJ18006 |
| the Cancer Research Funding of CSCO-Hausen |
Y-HS2019-5 |
|
| Corresponding Author |
Zhen-Yu Yin, PhD, Attending Doctor, Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China. lihuiying@njglyy.com |
| Key Words |
Non-small cell lung cancer; Central nervous system metastases; EGFR mutation; Pulsatile icotinib; Case report; |
| Core Tip |
Central nervous system (CNS) metastases are a catastrophic complication of non-small cell lung cancer (NSCLC) and always accompanied by poor prognosis. We report a patient who was diagnosed with CNS metastases from NSCLC with a targeted mutation in epidermal growth factor receptor. A standard dosage of icotinib (125 mg three times daily) was implemented but ineffective. So pulsatile icotinib (1125 mg every 3 d) was administered. This new strategy for administration resulted in complete remission of neurological symptoms, almost vanished lesions, and longer survival without notable side effects, providing a new alternative for the treatment of CNS metastases. |
| Publish Date |
2020-01-17 04:08 |
| Citation |
Li HY, Xie Y, Yu TT, Lin YJ, Yin ZY. Durable response to pulsatile icotinib for central nervous system metastases from EGFR-mutated non-small cell lung cancer: A case report. World J Clin Cases 2020; 8(2): 370-376 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i2/370.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i2.370 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
